Navigation Links
Alexion Reports First Quarter 2008 Results
Date:4/30/2008

s, can enhance an overall understanding of Alexion's past financial performance and its prospects for the future. The non-GAAP financial measures are included with the intent of providing both management and investors with a more complete understanding of underlying operational results and trends. In addition, these non-GAAP financial measures are among the primary indicators Alexion management uses for planning and forecasting purposes and measuring the company's performance. These non-GAAP financial measures are not intended to be considered in isolation or as a substitute for GAAP figures. A reconciliation of the non-GAAP to GAAP figures follows this press release.

[ALXN-E]

This news release contains forward-looking statements, including statements related to guidance regarding anticipated financial results for 2008, potential benefits and commercial potential for Soliris, timing and effect of sales of Soliris in the United States and various European markets, status of reimbursement, price approval and funding processes in Europe, progress in developing commercial infrastructure, interest regarding Soliris in the patient, physician and payor communities and expectations about commencement of clinical trials and studies. Forward-looking statements are subject to factors that may cause Alexion's results and plans to differ from those expected, including for example, decisions of regulatory authorities regarding marketing approval or material limitations on the marketing of Soliris, delays in arranging satisfactory manufacturing capability and establishing commercial infrastructure, delays in developing or adverse changes in commercial relationships, the possibility that results of clinical trials of Soliris are not predictive of safety and efficacy and Soliris is found to be less safe or effective when utilized in broader patient populations, the possibility that initial results of commercialization are not predictive of future rates of adoption of S
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Alexion to Present at Bear Stearns Healthcare Conference
2. Alexion Pharmaceuticals Invites You to Participate in its Fourth Quarter and Full Year 2007 Results Conference Call and Web Cast
3. Alexion Acquires All Rights to OMRF Patents Related to Soliris(R)
4. Alexion Reports Fourth Quarter and Full Year 2007 Results
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. QMed, Inc. Reports July Medicare SNP Enrollments
7. Phlo Affiliate Reports Expanded Coverage to Oregon Border
8. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Carrington Reports Second Quarter 2007 Results
11. Avitar Reports Third Quarter Financial Results for Fiscal 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 23, 2013 VG Energy, an agricultural ... DAK Renewable Research to conduct field trials using ... Energy is a majority owned subsidiary of VG ... VG Energy,s exclusively licensed compound LipidMax selectively inhibits ... in plants, possessing a wide variety of applications ...
(Date:5/23/2013)... May 23, 2013 On April 19th ... to supermarkets to search for the growing antibiotic resistant ... Results from a year long study were released late ... foods, specifically meats, over previous years. For those suffering ... growth of antibiotic resistant bacteria in food, may eventually ...
(Date:5/23/2013)... Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and ... a teleconference to discuss its First Quarter 2013 financial ... information is provided below: Date: Thursday, May ... Dial-in: (800) 875-3456 (U.S.); (800) 648-0973 ( ... For those unable to participate in the ...
(Date:5/23/2013)... Tucson, Ariz. (PRWEB) May 23, 2013 ... world’s first and only FDA, Health Canada and CE ... Glasgow Science Centre in Scotland, which boasts more than ... Total Artificial Heart powered by the Freedom® portable ... one of the most advanced exhibitions of its kind. ...
Breaking Biology Technology:VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 3Acne Cream, Probiotic Action Shares News on How Some Food may Breed Acne Causing Bacteria 2Pressure BioSciences, Inc. to Discuss First Quarter 2013 Financial Results and Provide Business Update 2SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 2SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 3
... CITY, Mo., Aug. 28 Truman Medical Centers (TMC),became ... to install the,Siemens SOMATOM Definition AS 128 slice CT ... adaptive scanner, providing exceptional image,quality with minimal radiation exposure ... first medical facilities in the country to have this,truly, ...
... (NYSE: BRL ) today announced that its ... U.S. Food & Drug Administration,(FDA) to manufacture and ... (galantamine hydrobromide), 4 mg, 8 mg and 12 ... tablets product immediately., Barr filed an Abbreviated ...
... Brussels: THR), a biotechnology company focused on innovative,treatments ... today issuing a,business update and its financial results ... During the first half of 2008, ThromboGenics ... positioned the Company to successfully pursue the,next stage ...
Cached Biology Technology:Truman Medical Centers Becomes One of the First Hospitals in the U.S. To Install the World's First Adaptive 128-slice CT Scanner 2Barr Receives Approval for Generic Version of Razadyne(R) Tablets 2Barr Receives Approval for Generic Version of Razadyne(R) Tablets 3Barr Receives Approval for Generic Version of Razadyne(R) Tablets 4Barr Receives Approval for Generic Version of Razadyne(R) Tablets 5ThromboGenics Announces Half Year Results 2008 2ThromboGenics Announces Half Year Results 2008 3ThromboGenics Announces Half Year Results 2008 4ThromboGenics Announces Half Year Results 2008 5
(Date:5/23/2013)... be the world,s most popular fruit, can be made ... purple GM varieties. , "Working with GM tomatoes ... addition of a specific compound, allows us to pinpoint ... Cathie Martin from the John Innes Centre. , The ... flavour, health and shelf life characteristics because even higher ...
(Date:5/23/2013)... nucleosomes in the cell nucleus makes it unavailable ... in Munich now describes a mechanism that allows ... for transcription. , In higher organisms the genomic ... around disk-shaped particles called nucleosomes, each consisting of ... accommodating two loops of DNA. Packed in this ...
(Date:5/23/2013)... are billions of animal and plant specimens from birds, ... stacked, stored and preserved in jars and collection drawers. ... to understanding how the Earth,s biodiversity is changing in ... only the information were easily accessible. , A new ... a team from the University of Colorado Boulder, is ...
Breaking Biology News(10 mins):The world's favorite fruit only better-tasting and longer-lasting 2Biochemistry: Unspooling DNA from nucleosomal disks 2CU-Boulder helps tap crowds to digitize museum records of bugs and plants 2CU-Boulder helps tap crowds to digitize museum records of bugs and plants 3CU-Boulder helps tap crowds to digitize museum records of bugs and plants 4
... a spin-off of the Universitat Autònoma de Barcelona, in ... developed an artificial cellular model which faithfully reproduces the ... the carrying out of various lines of research related ... use live animals. , The basic structure of skin ...
... Pretreatment with double-dose anticlotting medication just before percutaneous coronary ... and cardiac death by half, according to a study ... Society for Cardiovascular Angiography and Interventions (SCAI), May 9?2, ... giving patients at least 600 mg of clopidogrel before ...
... Pigs carry hepatitis E virus (HEV), which they can pass ... Online Open Access journal BMC Veterinary Research says that pigs ... infection. The scenario humans need to worry about would occur ... rates, there is actually a higher chance pigs will pass ...
Cached Biology News:High-dose anticlotting drug cuts heart attack, death risk in half 2